AI revolutionizes research: A new era for scientific discovery
Singularity Hub - 07-Oct-2024Balancing productivity gains with the risk of low-quality research
Join the club for FREE to access the whole archive and other member benefits.
Company developing patient-specific immunotherapies for cancer.
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
Visit website: https://biontech.de/
Details last updated 10-Jun-2020
Balancing productivity gains with the risk of low-quality research
New mRNA-based vaccine takes center stage in promising lung cancer care
mRNA cocktail treatment shows anti-tumor effect without toxic side effects in mice
Science behind developing Covid-19 vaccines could bring us cancer shots too
Developed through a novel mRNA technology used in vaccine for COVID-19
Six melanoma patients given an experimental, custom-made, neoantigen vaccine. None of their tumo...
What if we could send the body an instruction to produce its own drug? RNA strand seems easier t...